NEW YORK, March 3, 2025 -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Merck and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until April 14, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Merck securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On July 30, 2024, Merck issued a press release announcing its financial results for the second quarter of 2024 and held an associated earnings call. Among other items, Merck announced a significant reduction in demand in China for its HPV vaccination Gardasil, resulting in higher than normal inventory levels at Merck's distributor in China. Accordingly, the Company advised that shipments of Gardasil to China might fall below contracted levels for 2024.
On this news, Merck's stock price fell $12.53 per share, or 9.81%, to close at $115.25 per share on July 30, 2024.
Then, on February 4, 2025, Merck announced that it would no longer achieve the long-forecasted target of $11 billion in Gardasil sales by 2030, as the Company planned to cease Gardasil shipments to China "through at least midyear" to facilitate a "rapid reduction of inventory."
On this news, Merck's stock price fell $9.05 per share, or 9.07%, to close at $90.74 per share on February 4, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
